Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/4/22 → 1/29/25 |
Funding
- BeiGene Switzerland GmbH: $113,281.00
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patient
- Hao, Zhonglin (PI)